PRODUCT TYPES – Page 31

Analytical similarity failure (Tier 1 CQAs) during comparability protocol execution: CAPA strategy to restore similarity and prevent regulatory delays

Identifying the initial signals of analytical similarity failure is critical to initiating the investigation process. Symptoms may vary depending on testing methodologies and specific CQAs being assessed. Common signals include:Click…

Sterility assurance gap during transport to clinic: CAPA under time-critical constraints

Identifying symptoms or signals when a sterility assurance gap occurs is the first crucial step in initiating an investigation. Common symptoms may include:Click to read the full article.

Analytical similarity failure (Tier 1 CQAs) after downstream resin change: FDA/EMA expectations for root cause, rework, and comparability justification

Identifying the symptoms of an analytical similarity failure following a change in downstream resin is critical to initiating a timely investigation. Symptoms may manifest as discrepancies in analytical results that…

Sterility assurance gap during transport to clinic: regulatory deviation handling

Identifying initial symptoms or signals is essential when a potential sterility assurance gap comes to light during transport to clinics. Common indicators might include:Click to read the full article.

Biosimilar potency OOS vs reference product after downstream resin change: risk assessment for critical quality attributes and clinical impact

Identifying symptoms or signals is the initial step in recognizing a potency out-of-specification (OOS) case, particularly following a resin change in downstream processing. Common signals may include:Click to read the…

Sterility assurance gap during dispensing: patient safety assessment

Identifying symptoms or signals of sterility assurance gaps requires vigilance in operations. Some common indicators may include:Click to read the full article.

Biosimilar stability comparability failure during analytical similarity assessment: inspection-ready evidence pack for comparability and lifecycle management

The first step in addressing a stability comparability failure is recognizing the warning signs. Symptoms can manifest in various forms, and understanding these early indicators is critical to initiating a…

Sterility assurance gap during inspection readiness: regulatory deviation handling

Identifying symptoms or signals indicative of a sterility assurance gap is the first step in conducting an effective investigation. Common signals can arise from routine microbiological testing, material inspections, or…

Biosimilar stability comparability failure during stability pull comparisons: FDA/EMA expectations for root cause, rework, and comparability justification

Identifying symptoms early in the process is crucial for effective intervention. Symptoms that may indicate a stability comparability failure in biosimilars can emerge from several sources:Click to read the full…

Half-life deviation during inspection readiness: regulatory deviation handling

Identifying symptoms or signals of half-life deviations during routine inspections or lab tests is the first step in a timely and effective response. Symptoms may manifest through:Click to read the…

Analytical similarity failure (Tier 1 CQAs) after cell line or upstream change: inspection-ready evidence pack for comparability and lifecycle management

The detection of analytical similarity failures can stem from various sources, including routine testing of product batches or stability assessments. Common symptoms include:Click to read the full article.

Residue limit non-compliance during stability studies: GMP investigation and CAPA

The initial detection of residue limit non-compliance may occur in various ways, often manifesting during routine stability studies or through unexpected laboratory test results. Common signals include:Click to read the…